Who are we?
BioAvenir is a family owned pharmaceutical company specializing in licensing, registering and commercializing pharmaceuticals and special products in Israel both to the private and institutional market. The Company is registered in Israel and initiated its marketing actively during the second half of 2004. The company’s shareholders are engaged in a business activity In the United Kingdom.
Our Vision
To be a qualified agent for foreign pharmaceutical companies in Israel.
To be a cooperation partner for small to medium size companies within the field of pharmaceutical and biotechnology.
Core Business
Licensing -BioAvenir has formed partnerships with several companies operating in regulated markets, mainly in the EU and North America. These partnerships consist of license and long term supply agreements. With BioAvenir’s ability to register and market products in Israel, and it’s desire to form long term supply partnership, BioAvenir is the ideal partner for medium sized pharmaceutical and biotechnology companies.
Sales and Marketing – BioAvenir aims mainly to an added value generic products for hospitals, “difficult generic” which have an advantage over potential competitors, Medical devices and specialty drugs.
Sales and Marketing – BioAvenir aims mainly to an added value generic for hospitals, difficult generic, biosimilar, pain management drugs, drugs to treat rare diseases / orphan drugs, niche RX specially drugs.
Our Values & Competencies
Excellent business relationship with major institutions- health services providers and hospitals. Regulatory and registration expertise.Dedicated to high quality. Well acquaintance and experience in the field of Ophthalmology. Excellent personal relationship with opinion and policy leaders.
Our Strengths
- Excellent personal and business relationship with major institutions- health organizations and hospitals.
- Regulatory and registration expertise.
- Dedication to high quality.
- Excellent personal relationship with KOL’S.
International activity
BioAvenir’s shareholders have established a pharmaceutical company in Cyprus, called Nespera Pharma. Nespera is specializing in licensing and commercializing of pharmaceuticals and special products outside of Israel, mainly in North America and Europe. We have also established a company based In the United Kingdom which is dedicated to the development and commercializing of products in the field of pulmonary hypertension and cognitive, muscular and endocrine disorder.
Drugs Disributed by BioAvenir Ltd
Nucleotide Reverse Transcriptase Inhibitor. Aciclovir 250 mg. VIALS (pwdr. for sol. for IV inject): 5 x 10
ml. See lit.
Tmt. herpes simplex infects., severe initial
genital herpes in non-immune comp.
pts., prophylax. herpes simplex infects. in
immune-comp. pts. Tmt. varicella zoster
infects., herpes simplex encephalit.,
herpes simplex infects. in neonate/infant
up to 3 mths old.
Penicillin, β Lactamase Inhibitors. Clavulanic Acid (as potassium clavulanate) 200 mg/vial, Amoxycillin (as sodium) 1,000 mg/vial. VIALS (sol. for inject.): 1, 10, 100X20 ml. I.V. See lit.
Short-term tmt. bact. infects. caused by
suscept. organs. resist. to other betalactamase
inhibitors.
C/I: Hypersensitivity to the active substances or to any of the penicillins.
History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).
History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid
NSAID. Diclofenac Sodium 0.1%. EYE DROPS: 5, 30 x 0.5 ml. See lit.
Inflamm./painful states of non-infect.
origin, affect. ant. segment eye (espec. aft.
cataract surg).
Carbonic Anhydrase Inhibitor, β Antagonist. Dorzolamide HCl 20 mg/ml, Timolol Maleate 5 mg/ml. SOL.:5 ML. 1dr ×2/d in the affected eye. See lit.
For the tmt. of elevat. intraoc. press. (IOP) in pts. with ocular hypertens., open-ang. glauc., or other second. open-ang. glauc. when concom. ther. is appropr.
C/I: Hypersens. Pts. with past/present pulmon. dis. e.g.: asthma, severe chron. obstruct. bronchit. Pts. with bradycard., HF, arrhythm. Pts. with renal impair.,renal dis., nephrolithias. Pts. with hyperchlorem. acidosis.
Loop Diuretic. Furosemide 250 mg/25 ml. Vials. Sol. for inf. 50X 250 mg/25 ml:
For adlts., max recomm. dose is 1,500 mg/d, may reach 2,000 mg in except. cases.
For childr., max recomm. dly dose for parenteral admin. is 1 mg of furosemide per kg of BW up to a max of 20 mg.
Potent diuretic when a prompt and effect. diuresis is req.
Appropr. for emerg. or where oral ther. is not feasible. for cardiac, pulm., hepatic and renal oedema
C/I: Hypersens. to amiloride, sulphonamides or sulphonamide derivatives/ Hypovol. and dehydr. (with or without hypotension)/ Severe hypokalemia: severe hyponatremia/ Comatose or pre-comat. states assoc. with hepatic cirrh./ Anuria or renal fail. with anuria not resp. to furosemide, renal fail. as a result of poison. by nephrotox. or hepatotox. agents, renal fail. assoc. with hepat. coma/ Imp. renal funct. with creat. clear. below 30 ml/min per 1.73 m2 body surf. area/ Addison's disease/ Digitalis intox/ Porphyria/ Breast-feed.
Retinoid. Isotretinoin 5 mg, 10 mg, 20 mg, 40 mg. Soft gel caps 30 X 5/10/20/40 mg
Capsules to be taken with food 1 once or twice /d. Adults and adolescents>12:Start at a dose of 0.5 mg/kg dly. Adjust dose indiv. For most pts., from 0.5-1.0 mg/kg/d. Long-term remission and relapse rates are more closely rel. to total dose admin. than to either duration of tmt. or dly. dose. No substant. addit. benefit to be expected beyond a cumulative dose of 120-150 mg/kg. Duration of tmt. will depend on dly. dose. A tmt. course of 16-24 weeks is normally suffic. to achieve remission. In the majority of pts., complete clearing of acne is obtained with a sgle. course. In the event of a definite relapse at least 8 weeks after discontinuat., a further course may be considered using same dly. and cumulative dose.
For the tmt. of sev. cystic acne that does not respond to other tmt.
C/I: Hypersens.
Pregn. or breastf.
Women of childbearing potent. unless all of the condit. of the Pregn. Prevent. Progr.are met. Teratogenic
• hepatic insuffic.
• excess. elev. blood lipid values
• hypervitaminosis A
• concomitant treatment with tetracyclines
